RMTG CEO says Nasdaq uplisting remains long-term goal, timing uncertain

• Regenerative Medical Technology Group management outlined a Nasdaq uplisting plan tied to meeting exchange financial and float thresholds, without timing guidance.
• Management flagged rising liabilities, interest expense, derivatives, tied to funding growth and acquisitions; strategy centers on scaling higher-margin recurring revenue.
• Q1 2026 revenue rose 90% year over year; Q2 revenue quadrupled, supported by education-led growth through ISSCA and related product pull-through.
• BKFC partnership positioned as a marketing and clinical channel; management expects additional public announcements, citing fighter Ben Rothwell treatment.
• ISSCA Ai described as a physician tool built on 30 years of 60 million redacted records, aimed at deepening member relationships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenerative Medical Technology Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-093220), on August 25, 2026, and is solely responsible for the information contained therein.